Immune-Related Adverse Events of Genitourinary Cancer Patients, a Retrospective Cohort Study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have become common lines of therapy for genitourinary cancers (GUcs). Given their widespread use, understanding the risk factors, comparative profiles, and timing of immune-related adverse events (irAEs) is essential.

Methods

We created an IRB-approved retrospective registry of all patients who received at least one dose of an ICI for any indication between 1 February 2011 and 7 April 2022 at a comprehensive cancer center and its outreach clinics. Dichotomous outcomes were modeled using multivariable logistic regression. Survival outcomes were compared using multivariable Cox regression.

Results

Among 3101 patients, 196 had renal cell carcinoma (RCC) and 170 had urothelial tumors. RCC patients were more likely to experien

SUBMITTER: Hunting JC 

PROVIDER: S-EPMC11394475 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature